February 28, 2025

New Publication from CeMOS: Exploring the Aβ Plaque Microenvironment in Alzheimer’s Disease Model Mice by Multimodal Lipid-Protein-Histology Imaging on a Benchtop Mass Spectrometer

New Publication from CeMOS: Exploring the Aβ Plaque Microenvironment in Alzheimer’s Disease Model Mice by Multimodal Lipid-Protein-Histology Imaging on a Benchtop Mass Spectrometer

Müller, E.; Enzlein, T.; Niemeyer, D.; von Ammon, L.; Stumpo, K.; Biber, K.; Klein, C.; Hopf, C. Exploring the Aβ Plaque Microenvironment in Alzheimer’s Disease Model Mice by Multimodal Lipid-Protein-Histology Imaging on a Benchtop Mass Spectrometer. Pharmaceuticals 202518, 252. https://doi.org/10.3390/ph18020252

Abstract

Amyloid-β (Aβ) plaque deposits in the brain are a hallmark of Alzheimer’s disease (AD) neuropathology. Plaques consist of complex mixtures of peptides like Aβ1–42 and characteristic lipids such as gangliosides, and they are targeted by reactive microglia and astrocytes. Background: In pharmaceutical research and development, it is a formidable challenge to contextualize the different biomolecular classes and cell types of the Aβ plaque microenvironment in a coherent experimental workflow on a single tissue section and on a benchtop imaging reader. Methods: Here, we developed a workflow that combines lipid MALDI mass spectrometry imaging using a vacuum-stable matrix with histopathology stains and with the MALDI HiPLEX immunohistochemistry of plaques and multiple protein markers on a benchtop imaging mass spectrometer. The three data layers consisting of lipids, protein markers, and histology could be co-registered and evaluated together. Results: Multimodal data analysis suggested the extensive co-localization of Aβ plaques with the peptide precursor protein, with a defined subset of lipids and with reactive glia cells on a single brain section in APPPS1 mice. Plaque-associated lipids like ganglioside GM2 and phosphatidylinositol PI38:4 isoforms were readily identified using the tandem MS capabilities of the mass spectrometer. Conclusions: Altogether, our data suggests that complex pathology involving multiple lipids, proteins and cell types can be interrogated by this spatial multiomics workflow on a user-friendly benchtop mass spectrometer.

Our latest News

discover more
Workflow Optimisation in the Laboratory: Premiere of the smartLabs Summit in Heidelberg

Workflow Optimisation in the Laboratory: Premiere of the smartLabs Summit in Heidelberg

On September 24, 2025, the smartLabs Summit will open its doors for the first time in Heidelberg – an event dedicated to practical innovation, digitalization, and automation in laboratories. The Summit will take place at BioLabs Heidelberg (Nicola-Tesla Straße 1–3, 69124 Heidelberg) and offers a full program from 1:00 to 7:30 p.m. Initiated by the […]

DFG awards Heidelberg research project on early detection of spinal degeneration nearly €250,000 in funding

DFG awards Heidelberg research project on early detection of spinal degeneration nearly €250,000 in funding

The aim of the project is to use special quantitative MRI to visualize early changes in the intervertebral disc and enable timely treatment. Ultrashort echo time (UTE) MRI opens up completely new approaches to preventive imaging that are difficult or impossible to achieve with conventional MRI methods. Full text in German below. DFG fördert Heidelberger […]

Glioblastoma study shows: Molecular diagnostics could enable targeted therapies without delay

Glioblastoma study shows: Molecular diagnostics could enable targeted therapies without delay

Researchers from Heidelberg University’s Medical Faculty, the German Cancer Research Center (DKFZ), and the National Center for Tumor Diseases (NCT) in Heidelberg have tested the use of targeted drugs in the initial treatment of newly diagnosed glioblastoma, an extremely aggressive brain tumor, in the multicenter study “NCT Neuro Master Match (N2M2)”. Of the five drugs […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp